Obesity

In real-world data from adults with overweight or obesity, weekly semaglutide therapy of 1.7 mg or 2.4 mg was effective at 3 and 6 months for weight loss amounts similar to those observed in clinical trials, according to researchers.

SARS-CoV-2 infects adipose tissue, where it can act as an ongoing source of virus replication and inflammation, according to a study that may indicate why obesity has proven to be such a significant risk factor for severe COVID-19.

Compared with a low-fat diet, a personalized diet targeting postprandial glycemic response did not lead to greater weight loss at 6 months among adults with abnormal glucose metabolism and obesity, according to study data.

As a valued ally in delivering the latest news, resources and education to busy medical providers, Healio has committed its support to the 17th Annual Cardiometabolic Health Congress: The Present and Future of Cardiometabolic Health.

Adults with obesity — but not those with normal weight — who try to lose weight lower their risk for developing type 2 diabetes regardless of weight-loss strategy, according to study findings published in PLOS Medicine.

Adjusting pulmonary hemodynamics for esophageal pressure in patients with obesity and high pulmonary artery wedge pressure reduced the risk for postcapillary pulmonary hypertension diagnosis, according to findings published in Chest.

Once-weekly semaglutide 2.4 mg reduces the 10-year risk for developing type 2 diabetes by more than 60% for people with overweight or obesity, according to a speaker at the European Association for the Study of Diabetes annual meeting.

Adults who lose weight in the first 4 weeks of a behavioral weight-management program are more likely to have successful medium-term weight loss, according to a speaker at the European Association for the Study of Diabetes annual meeting.

Obesity is a complex disease with multifactorial etiology. Multidisciplinary care is an optimal way to support patients with short-term success, long-term weight loss maintenance, and the prevention of obesity-related complications.

Combined oral contraceptives were associated with an increased risk for thrombotic events in women with obesity, according to a recent review.